- Published on
Emergency and Acute Medicine: Sporotrichosis
Sporotrichosis is a subacute or chronic fungal infection caused by Sporothrix schenckii, a dimorphic organism found in soil, decaying vegetation, and organic matter. Infection typically occurs through traumatic inoculation into the skin, such as via thorns or splinters, or through animal scratches—particularly from cats. Less commonly, inhalation of fungal spores can lead to pulmonary disease. The condition is classically associated with occupational exposure among farmers, gardeners, and forestry workers, and is more severe in immunocompromised individuals.
The most common form is lymphocutaneous sporotrichosis, which begins as a painless papule at the site of inoculation that gradually enlarges into a nodule and may ulcerate. Over time, additional nodular lesions develop along the draining lymphatic channels, forming a characteristic chain-like pattern. These lesions are typically nonpurulent and only mildly painful, and systemic symptoms are usually absent. A fixed cutaneous form may also occur, presenting as a localized plaque or verrucous lesion without lymphatic spread.
More severe disease occurs in extracutaneous forms, particularly in immunocompromised patients. Osteoarticular sporotrichosis presents as a chronic, indolent infection involving joints such as the knee, wrist, or elbow, often mimicking other causes of arthritis. Pulmonary sporotrichosis resembles tuberculosis, with symptoms including cough, fever, weight loss, and hemoptysis, and can be fatal if untreated. Disseminated disease may involve multiple organ systems, including skin, bones, central nervous system, and eyes, and is associated with significant morbidity and mortality.
Diagnosis relies on isolating the organism from clinical specimens such as tissue biopsy, aspirate, sputum, or synovial fluid. Histologic examination may reveal characteristic “cigar-shaped” yeast forms, although cultures remain the gold standard. Routine blood tests are not particularly helpful in cutaneous disease but may assist in evaluating systemic involvement. Imaging studies are guided by clinical presentation, such as chest radiographs in pulmonary disease or bone scans in suspected disseminated infection.
Treatment depends on the severity and extent of disease. For cutaneous and lymphocutaneous forms, oral itraconazole is the treatment of choice and is continued for several weeks after lesion resolution. Alternatives include terbinafine or saturated potassium iodide solution, although the latter is less well tolerated. Local heat therapy may be used in selected patients who cannot tolerate medications. More severe infections, including pulmonary, osteoarticular, and disseminated forms, require prolonged antifungal therapy, often starting with amphotericin B followed by itraconazole. Immunocompromised patients, particularly those with HIV, may require long-term suppressive therapy.
Patients with localized cutaneous disease can usually be managed as outpatients, whereas those with systemic involvement or immunosuppression require hospital admission and specialist care. Early recognition is important, as delayed diagnosis—especially in disseminated disease—can lead to poor outcomes. A key clinical clue is a history of exposure to soil, plant material, or cats in combination with nodular skin lesions tracking along lymphatics.
Sporotrichosis is a subacute or chronic fungal infection caused by Sporothrix schenckii, a dimorphic organism found in soil, decaying vegetation, and organic matter. Infection typically occurs through traumatic inoculation into the skin, such as via thorns or splinters, or through animal scratches—particularly from cats. Less commonly, inhalation of fungal spores can lead to pulmonary disease. The condition is classically associated with occupational exposure among farmers, gardeners, and forestry workers, and is more severe in immunocompromised individuals.
The most common form is lymphocutaneous sporotrichosis, which begins as a painless papule at the site of inoculation that gradually enlarges into a nodule and may ulcerate. Over time, additional nodular lesions develop along the draining lymphatic channels, forming a characteristic chain-like pattern. These lesions are typically nonpurulent and only mildly painful, and systemic symptoms are usually absent. A fixed cutaneous form may also occur, presenting as a localized plaque or verrucous lesion without lymphatic spread.
More severe disease occurs in extracutaneous forms, particularly in immunocompromised patients. Osteoarticular sporotrichosis presents as a chronic, indolent infection involving joints such as the knee, wrist, or elbow, often mimicking other causes of arthritis. Pulmonary sporotrichosis resembles tuberculosis, with symptoms including cough, fever, weight loss, and hemoptysis, and can be fatal if untreated. Disseminated disease may involve multiple organ systems, including skin, bones, central nervous system, and eyes, and is associated with significant morbidity and mortality.
Diagnosis relies on isolating the organism from clinical specimens such as tissue biopsy, aspirate, sputum, or synovial fluid. Histologic examination may reveal characteristic “cigar-shaped” yeast forms, although cultures remain the gold standard. Routine blood tests are not particularly helpful in cutaneous disease but may assist in evaluating systemic involvement. Imaging studies are guided by clinical presentation, such as chest radiographs in pulmonary disease or bone scans in suspected disseminated infection.
Treatment depends on the severity and extent of disease. For cutaneous and lymphocutaneous forms, oral itraconazole is the treatment of choice and is continued for several weeks after lesion resolution. Alternatives include terbinafine or saturated potassium iodide solution, although the latter is less well tolerated. Local heat therapy may be used in selected patients who cannot tolerate medications. More severe infections, including pulmonary, osteoarticular, and disseminated forms, require prolonged antifungal therapy, often starting with amphotericin B followed by itraconazole. Immunocompromised patients, particularly those with HIV, may require long-term suppressive therapy.
Patients with localized cutaneous disease can usually be managed as outpatients, whereas those with systemic involvement or immunosuppression require hospital admission and specialist care. Early recognition is important, as delayed diagnosis—especially in disseminated disease—can lead to poor outcomes. A key clinical clue is a history of exposure to soil, plant material, or cats in combination with nodular skin lesions tracking along lymphatics.
0 Comments
